INTELLIGENT BIO SOLUTIONS INC. (INBS) - Dilution Analysis

10-Q filing | 2.4M shares outstanding

S-3 filing: This S-3 filing from Intelligent Bio Solutions Inc. relates to the resale of 6,896,550 shares of common stock by selling stockholders, acquired through a private placement, including shares already outstanding and shares issuable upon exercise of warrants.

8-K filing: Intelligent Bio Solutions Inc. sold 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 4,597,700 shares of common stock in a private placement offering, which closed on January 2, 2026. ($10.0M proceeds)

8-K filing: Stock split 1-for-10 | Outstanding: 8,546,934 → 959,533

8-K filing: Intelligent Bio Solutions Inc. approved the issuance of 75,000 restricted shares of Company common stock to MDM Worldwide Solutions, Inc. as equity compensation for strategic communication advisory and consulting services.

10-Q filing | 8.5M shares outstanding

S-3/A filing: Intelligent Bio Solutions, Inc. may issue up to $100,000,000 aggregate dollar amount of common stock, preferred stock, debt securities, warrants, purchase contracts, or units of securities in any combination.

10-K filing | 9.0M shares outstanding

10-Q filing | 6.9M shares outstanding

S-3 filing: The filing is an S-3 form for a shelf offering of up to $100,000,000 aggregate dollar amount of common stock, preferred stock, debt securities, warrants, purchase contracts, or units of securities.

8-K filing: Intelligent Bio Solutions Inc. completed a public offering of 1,500,000 shares of common stock at $2.00 per share, resulting in gross proceeds of $3.0 million and a total of 6,778,837 shares outstanding after the offering. ($3.0M proceeds)

10-Q filing | 5.3M shares outstanding

8-K filing: Intelligent Bio Solutions Inc. reports 4,807,068 shares of common stock outstanding as of January 2, 2025, following the sale of shares under the At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. and the issuance of restricted common stock under the Investor Relations and Corporate Development Advisory Agreement with ClearThink Capital Partners LLC.

8-K filing: The company raised approximately $250,802 (net of commissions) through the sale and issuance of shares of common stock pursuant to the ATM Agreement with Ladenburg Thalmann & Co. Inc. as of November 19, 2024. ($0.25M proceeds)

10-Q filing | 4.4M shares outstanding

10-K filing | 4.2M shares outstanding

10-Q filing | 3.1M shares outstanding

S-3 filing: Intelligent Bio Solutions, Inc. files an S-3 to register 6,781,166 shares of common stock for resale by selling stockholders, including shares acquired in a private placement and shares issuable upon exercise of warrants.

8-K filing: Intelligent Bio Solutions Inc. entered into a Securities Purchase Agreement for the sale of common stock and warrants in a private placement offering that closed on March 12, 2024, resulting in gross proceeds of approximately $10.1 million. ($10.1M proceeds)

S-3 filing: This S-3 filing registers 636,367 shares of common stock for resale by selling stockholders, issuable upon the exercise of warrants issued on February 7, 2024.

8-K filing: Intelligent Bio Solutions Inc. issued 37,500 restricted shares of common stock to C2C Advisors Inc. and 5,260 restricted shares of common stock to ClearThink Capital LLC for advisory and investor relations services.

10-Q filing | 2.1M shares outstanding

8-K filing: Intelligent Bio Solutions Inc. closed an offering on February 7, 2024, issuing 606,064 shares of common stock upon the exercise of existing warrants, generating gross proceeds of approximately $1.77 million before deducting closing costs and placement agent fees. ($0.0M proceeds)

8-K filing: Stock split 1-for-12 | Outstanding: 8,734,381 → 1,494,223

10-Q filing | 8.7M shares outstanding

8-K filing: Intelligent Bio Solutions Inc. closed a public offering on October 4, 2023, issuing 2,232,221 shares of Common Stock, 5,728,723 shares of Series E Preferred Stock, Series E Warrants to purchase 7,960,944 shares of Common Stock, and Series F Warrants to purchase 7,960,944 shares of Common Stock, with net proceeds of approximately $3.35 million.

S-1/A filing: This is an S-1/A filing for Intelligent Bio Solutions Inc. related to the offering of Class A Units consisting of shares of Common Stock, Series E Warrants and Series F Warrants and/or Class B Units consisting of shares of Series E Convertible Preferred Stock, Series E Warrants and Series F Warrants.

S-1/A filing: Intelligent Bio Solutions Inc. is offering 2,985,074 Class A Units consisting of shares of Common Stock, Series E Warrants and Series F Warrants and/or 2,985,074 Class B Units consisting of shares of Series E Convertible Preferred Stock, Series E Warrants and Series F Warrants.

S-1/A filing: This S-1/A filing outlines the general expenses related to the offering, including filing fees, legal counsel fees, and underwriter costs. It also mentions a management fee for the representative equal to 1.0% of the total gross proceeds raised in the Offering, and reimbursement for fees and expenses of legal counsel and other out-of-pocket expenses up to $145,000.

S-1/A filing: Intelligent Bio Solutions Inc. is offering 2,185,792 Class A Units consisting of shares of Common Stock and Series E Warrants and/or 2,185,792 Class B Units consisting of shares of Series E Convertible Preferred Stock and Series E Warrants at an assumed price of $1.83 per unit.

10-K filing | 2.3M shares outstanding

S-1/A filing: Preliminary prospectus for an offering of Class A Units consisting of common stock and warrants and Class B Units consisting of Series E Convertible Preferred Stock and warrants.

S-1 filing: This S-1 filing describes an offering of Class A Units (common stock and warrants) and Class B Units (Series E Convertible Preferred Stock and warrants) by Intelligent Bio Solutions Inc.

S-1/A filing: This S-1/A filing relates to the offer and sale of up to 823,736 shares of common stock by selling stockholders.

S-1 filing: This S-1 filing relates to the offer and sale of up to 822,164 shares of common stock by selling stockholders, including shares issued in connection with an acquisition, conversion of preferred stock, and underlying warrants.

8-K filing: Intelligent Bio Solutions Inc. converted convertible debt into shares of IFP, a subsidiary, which were then exchanged for 172,386 shares of the Company's common stock.

8-K filing: Intelligent Bio Solutions Inc. stockholders approved the conversion of Series C Convertible Preferred Stock and the issuance of common stock in connection with the conversion related to the acquisition of Intelligent Fingerprinting Limited. 1,149,273 shares of Series C Preferred Stock were convertible into 172,386 shares of Common Stock as of May 10, 2023.

10-Q filing | 1.7M shares outstanding

8-K filing: Intelligent Bio Solutions Inc. completed a public offering of 654,990 shares of common stock and warrants to purchase 196,497 shares, with gross proceeds of approximately $2.55 million after fully exercising the over-allotment option. ($2.55M proceeds)

10-Q filing | 0.9M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 18,352,995 → 916,265

8-K filing: Intelligent Bio Solutions Inc. closed a private placement issuing 176,462 shares of Series D Convertible Preferred Stock and 529,386 warrants for gross proceeds of $220,585, with a portion of the funds secured from senior management. ($0.22M proceeds)

10-Q filing | 18.4M shares outstanding

10-K filing | 14.7M shares outstanding

10-Q filing | 14.9M shares outstanding

S-3 filing: This S-3 filing indicates that the company may issue up to $100,000,000 of securities, including common stock, preferred stock, debt securities, warrants, or units, in any combination.

10-Q filing | 14.9M shares outstanding

10-Q filing | 14.9M shares outstanding

10-K filing | 13.6M shares outstanding

10-Q filing | 11.9M shares outstanding

8-K filing: As of February 12, 2021, the company reported 11,875,222 shares of common stock issued and outstanding, excluding shares reserved for future issuance under the 2019 Equity Incentive Plan and shares issuable upon the exercise of warrants. Since then, the number of shares of common stock issued and outstanding increased to 12,382,122 shares, representing an increase of 506,900 shares, including shares issued upon conversion of Series B preferred stock and exercise of warrants.

S-1/A filing: This prospectus relates to the offer and sale of up to 3,000,000 shares of our common stock issuable upon conversions of the Series B Convertible Preferred Stock by the selling stockholders.

S-1/A filing: This prospectus relates to the offer and sale of up to 3,000,000 shares of our common stock issuable upon conversions of the Series B Convertible Preferred Stock by the selling stockholders.

10-Q filing | 10.4M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 3,000,000 shares of common stock issuable upon conversions of the Series B Convertible Preferred Stock by the selling stockholders.

S-1/A filing: This is an initial public offering of units of our securities, including common stock, Series A warrants, and Series B warrants, with an expected initial public offering price between $16.00 and $18.00 per unit.

S-1/A filing: This is an initial public offering of units of securities, with each unit consisting of one share of common stock (or Series B Convertible Preferred Stock), one Series A warrant, and one Series B warrant. The initial public offering price is expected to be between $16.00 and $18.00 per unit.

S-1/A filing: Initial public offering of units consisting of common stock, Series A warrants, and Series B warrants, with an option for purchasers to substitute Series B Convertible Preferred Stock for common stock.

S-1/A filing: This is an initial public offering of units of our securities, consisting of common stock (or Series B Convertible Preferred Stock), Series A warrants, and Series B warrants. Subject to Completion, dated October 20, 2020.

S-1/A filing: This is an initial public offering of units of securities, including common stock, Series A warrants, and Series B warrants, with an expected initial public offering price between $16.00 and $18.00 per unit.

S-1/A filing: The company is filing an S-1/A to register an initial public offering of units, each consisting of one share of common stock (or Series B Convertible Preferred Stock), one Series A warrant, and one Series B warrant.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. The company has applied to list its common stock on the NASDAQ Global Market under the symbol "GBSG".